Mechanism of action
Hydromorphone is a pure μ-opioid receptor agonist that acts primarily on μ-receptors in the central nervous system and periphery. Binding to these G-protein coupled receptors leads to inhibition of adenylyl cyclase, decreased cAMP production, and reduced calcium influx into presynaptic neurons. This results in decreased release of excitatory neurotransmitters including substance P and glutamate.
Postsynaptically, μ-receptor activation causes hyperpolarization through increased potassium efflux, making neurons less excitable. These combined effects interrupt ascending pain pathways in the spinal cord and modulate pain perception in supraspinal sites including the periaqueductal gray and rostral ventromedial medulla.
Hydromorphone has minimal affinity for κ- and δ-opioid receptors. Unlike morphine, it lacks clinically significant active metabolites with analgesic activity, making it more predictable in patients with renal impairment. Its lipophilicity allows for good CNS penetration and rapid onset of analgesia.
- Hydromorphone is 5-7 times more potent than morphine; equianalgesic conversion errors are a common cause of overdose
- Preferred over morphine in renal failure due to lack of active analgesic metabolites
- Metabolized via glucuronidation, not CYP450 enzymes, minimizing drug-drug interactions
- Respiratory depression is the most serious adverse effect, highest risk with rapid IV push
- Constipation does not develop tolerance; prophylactic bowel regimen mandatory
- Black box warning for concomitant use with benzodiazepines causing profound respiratory depression and death
- Physical dependence develops with chronic use; abrupt discontinuation causes withdrawal syndrome
- Naloxone reverses overdose but has shorter duration than hydromorphone, requiring monitoring for re-sedation
Indications
Hydromorphone is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It is used in both acute and chronic pain settings.
Acute pain management:
- Postoperative pain
- Traumatic injuries
- Acute painful medical conditions (myocardial infarction, pancreatitis, renal colic)
- Cancer-related pain exacerbations
Chronic pain management:
- Cancer pain (extended-release formulations)
- Palliative care
- Severe chronic pain unresponsive to non-opioid analgesics
Route-specific uses:
- Parenteral forms are preferred when oral administration is not feasible (nausea, vomiting, altered consciousness, NPO status)
- Patient-controlled analgesia (PCA) pumps for postoperative pain
- Continuous subcutaneous or intravenous infusions in palliative care
Hydromorphone is often chosen over morphine in patients with renal insufficiency due to lack of active metabolite accumulation. Extended-release formulations provide around-the-clock analgesia for chronic pain requiring continuous opioid therapy.
Pharmacokinetics
Absorption: Oral bioavailability is approximately 30-35% due to significant first-pass metabolism. Peak plasma concentrations occur 30-60 minutes after oral immediate-release dosing and 12-16 hours with extended-release formulations. Parenteral administration bypasses first-pass metabolism, providing 100% bioavailability.
Distribution: Hydromorphone is moderately lipophilic with a volume of distribution of approximately 4 L/kg. It is 8-19% protein-bound. It crosses the blood-brain barrier readily and crosses the placenta. Small amounts appear in breast milk.
Metabolism: Primarily hepatic via glucuronidation to hydromorphone-3-glucuronide (H3G), the major metabolite. Unlike morphine-6-glucuronide, H3G has no analgesic activity but may accumulate in renal failure and potentially contribute to neuroexcitatory effects. Minor pathways include N-demethylation and 6-keto reduction. Metabolism is not dependent on CYP450 enzymes.
Elimination: Renal excretion is the primary route of elimination, with approximately 7% excreted unchanged in urine and the remainder as conjugated metabolites. The elimination half-life is 2-3 hours for immediate-release formulations. Duration of analgesia is typically 4-5 hours for immediate-release oral and 3-4 hours for parenteral administration. Extended-release formulations provide 24-hour analgesia.
Special populations: Clearance is reduced in elderly patients and those with hepatic or renal impairment, necessitating dose adjustments.
Adverse effects
Central nervous system:
- Sedation and drowsiness (very common)
- Dizziness and lightheadedness
- Confusion, especially in elderly
- Euphoria or dysphoria
- Headache
- Myoclonus (with high doses or accumulation)
Respiratory:
- Respiratory depression (dose-dependent, most serious adverse effect)
- Decreased respiratory rate and tidal volume
- Risk increased with rapid IV administration, high doses, or concurrent CNS depressants
Gastrointestinal:
- Nausea and vomiting (common, often transient)
- Constipation (very common, does not develop tolerance)
- Dry mouth
- Biliary spasm
Cardiovascular:
- Orthostatic hypotension
- Bradycardia
- Peripheral vasodilation
- Histamine release with rapid IV injection (flushing, pruritus, hypotension)
Genitourinary:
- Urinary retention
- Decreased libido
- Erectile dysfunction with chronic use
Endocrine:
- Hypogonadism with chronic use (decreased testosterone and estrogen)
- Secondary amenorrhea
Other:
- Pruritus (itching)
- Diaphoresis
- Miosis (pinpoint pupils)
Dependence and withdrawal: Physical dependence develops with regular use. Abrupt discontinuation or administration of opioid antagonists precipitates withdrawal syndrome characterized by anxiety, restlessness, mydriasis, lacrimation, rhinorrhea, piloerection, diaphoresis, diarrhea, muscle aches, and yawning. Psychological dependence and addiction potential are significant concerns requiring careful patient selection and monitoring.
Contraindications and warnings
Absolute contraindications:
- Significant respiratory depression or acute/severe bronchial asthma in unmonitored settings
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Hypersensitivity to hydromorphone or any formulation component
Black box warnings:
- Addiction, abuse, and misuse: Opioids carry risk of addiction even at therapeutic doses
- Life-threatening respiratory depression: Highest risk during initiation and dose increases
- Neonatal opioid withdrawal syndrome: Prolonged use during pregnancy causes withdrawal in newborns
- Concomitant use with benzodiazepines or CNS depressants: Profound sedation, respiratory depression, coma, and death
- Accidental ingestion: Even one dose can be fatal in children
- Cytochrome P450 3A4 interaction: (less relevant for hydromorphone but included in class labeling)
Warnings and precautions:
- Elderly patients: Increased sensitivity to respiratory and CNS effects
- Renal/hepatic impairment: Dose reduction required; metabolite accumulation possible
- Head injury or increased intracranial pressure: May obscure neurologic assessment and impair ventilatory response to CO₂
- Hypotension/shock: Opioids can exacerbate hypotension
- Adrenal insufficiency: Opioids reported to cause adrenal insufficiency
- Seizure disorders: May lower seizure threshold
- Biliary tract disease: Sphincter of Oddi spasm can worsen symptoms
- Prostatic hypertrophy/urethral stricture: Urinary retention risk
- Hypothyroidism, Addison disease, toxic psychosis: Use with extreme caution
Pregnancy and lactation: Pregnancy Category C (previously). Opioids cross the placenta; chronic use during pregnancy causes neonatal opioid withdrawal syndrome requiring management. Use only if benefits outweigh risks. Hydromorphone appears in breast milk; monitor infants for sedation and respiratory depression or consider alternative feeding.
Drug interactions
CNS depressants (major interaction): Concomitant use with benzodiazepines, barbiturates, sedative-hypnotics, anxiolytics, general anesthetics, phenothiazines, tranquilizers, alcohol, or other opioids results in profound sedation, respiratory depression, coma, and death. Avoid combination when possible; if necessary, use lowest effective doses and monitor closely.
Serotonergic drugs: Combination with SSRIs, SNRIs, TCAs, triptans, 5-HT3 antagonists, MAOIs, or linezolid may result in serotonin syndrome (agitation, hyperthermia, hyperreflexia, incoordination, diarrhea). MAOIs require 14-day washout period before opioid administration.
Mixed agonist/antagonist and partial agonist opioids: Buprenorphine, nalbuphine, butorphanol, and pentazocine may reduce hydromorphone's analgesic effect or precipitate withdrawal in opioid-dependent patients. Avoid concurrent use.
Anticholinergic drugs: Additive effects may increase risk of urinary retention, severe constipation, or paralytic ileus.
Muscle relaxants: Enhanced neuromuscular blocking effect and increased degree of respiratory depression.
Diuretics: Opioids may reduce diuretic efficacy by inducing antidiuretic hormone release.
CYP450 interactions: Unlike many opioids (such as codeine, oxycodone, and fentanyl), hydromorphone is metabolized primarily via glucuronidation rather than CYP450 enzymes, making it less susceptible to CYP-mediated drug interactions.
Naloxone/naltrexone: Opioid antagonists reverse hydromorphone's effects and may precipitate acute withdrawal in dependent patients. Naloxone is used to reverse respiratory depression in overdose.
Clinical pearls
Equianalgesic dosing: Hydromorphone is approximately 5-7 times more potent than morphine. A common conversion is 1.5 mg parenteral hydromorphone ≈ 10 mg parenteral morphine. Prescribing errors with conversion are a common cause of overdose. Always verify calculations.
Renal impairment advantage: Unlike morphine, hydromorphone lacks active analgesic metabolites that accumulate in renal failure. While the inactive metabolite H3G may accumulate, hydromorphone is often preferred over morphine in patients with significant renal dysfunction.
IV administration: Administer slow IV push over 2-3 minutes to minimize histamine release, which can cause hypotension, flushing, and pruritus. Rapid injection increases respiratory depression risk.
PCA dosing: Hydromorphone is commonly used in PCA pumps. Typical demand doses are 0.2-0.4 mg with 5-10 minute lockout intervals. Continuous basal infusions increase risk of respiratory depression.
Constipation management: Unlike other opioid side effects, tolerance to constipation does not develop. Prophylactic bowel regimen with stimulant laxatives (senna, bisacodyl) and stool softeners is essential for all patients on scheduled opioids.
Rotation strategy: Hydromorphone is commonly used in opioid rotation for patients with incomplete analgesia or intolerable side effects on other opioids. Incomplete cross-tolerance exists; reduce the equianalgesic dose by 25-50% when rotating.
Extended-release formulations: Reserved for opioid-tolerant patients requiring around-the-clock analgesia. Never crush, chew, or dissolve extended-release tablets—doing so causes rapid release and potentially fatal overdose.
Naloxone reversal: In overdose, naloxone 0.4-2 mg IV/IM/SC reverses respiratory depression. Effect duration (30-90 minutes) is shorter than hydromorphone's, requiring monitoring and potential re-dosing. In opioid-dependent patients, titrate carefully to avoid precipitating severe withdrawal.
Exam tip: Questions often test equianalgesic conversion errors, respiratory depression recognition, or appropriate use in renal failure versus morphine.
Practice questions
1. A 68-year-old man with stage IV pancreatic cancer and chronic kidney disease (eGFR 25 mL/min/1.73m²) presents with severe abdominal pain inadequately controlled on oral morphine 30 mg every 4 hours. He experiences confusion and myoclonus. Creatinine has risen from 2.1 to 2.8 mg/dL over the past week. Which medication change is most appropriate?
2. A 45-year-old woman is receiving hydromorphone 0.4 mg IV every 3 hours via PCA pump following abdominal surgery. On post-operative day 2, nursing staff finds her difficult to arouse with a respiratory rate of 6 breaths per minute and oxygen saturation of 84% on room air. Which of the following is the most appropriate immediate intervention?
3. A 72-year-old man hospitalized for hip fracture requires opioid analgesia. His medications include alprazolam 0.5 mg three times daily for generalized anxiety disorder, which he has taken for 5 years. He has normal renal and hepatic function. What is the most appropriate prescribing approach?
Frequently asked questions
How does hydromorphone work?
Hydromorphone works by binding to μ-opioid receptors in the brain and spinal cord, inhibiting pain signal transmission. It activates G-protein coupled receptors that reduce excitatory neurotransmitter release and hyperpolarize neurons, decreasing pain perception. The drug is approximately 5-7 times more potent than morphine and provides rapid analgesia through central nervous system depression of pain pathways.
What are the side effects of hydromorphone?
The most serious side effect is respiratory depression, which can be life-threatening. Common side effects include sedation, dizziness, nausea, vomiting, and constipation (which does not improve with continued use). Other effects include urinary retention, itching, confusion in elderly patients, and orthostatic hypotension. Chronic use causes physical dependence and carries addiction risk. Rapid IV administration can cause histamine release with flushing and hypotension.
Is hydromorphone a controlled substance?
Yes, hydromorphone is a Schedule II controlled substance in the United States due to its high potential for abuse, addiction, and physical dependence. Schedule II designation means it has accepted medical uses but requires special prescribing rules including written prescriptions (limited electronic exceptions), no refills allowed, and strict record-keeping. Healthcare providers must register with the DEA to prescribe it, and pharmacies must maintain detailed inventory records.
Hydromorphone vs morphine — what is the difference?
Hydromorphone is 5-7 times more potent than morphine, requiring much smaller doses for equivalent analgesia. The key clinical difference is that hydromorphone is preferred in renal failure because it lacks active analgesic metabolites that accumulate, whereas morphine produces morphine-6-glucuronide which can accumulate and cause prolonged effects. Hydromorphone is metabolized via glucuronidation rather than CYP450 enzymes, reducing drug interaction potential. Both have similar side effect profiles, but hydromorphone has a slightly shorter duration of action.
Can hydromorphone be given IV push?
Yes, hydromorphone can be administered via slow IV push, but it must be given over 2-3 minutes to minimize adverse effects. Rapid IV injection increases the risk of severe respiratory depression, histamine release (causing hypotension, flushing, and pruritus), and cardiovascular effects. Healthcare providers should dilute the dose and administer slowly while monitoring vital signs, especially respiratory rate and oxygen saturation. Patient-controlled analgesia (PCA) pumps and continuous infusions are alternative IV administration methods.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N02AA03
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.